AVM
Arch Venture Management Portfolio holdings
AUM
$299M
This Quarter Return
+46.75%
1 Year Return
-19.47%
3 Year Return
-31.35%
5 Year Return
–
10 Year Return
–
AUM
$771M
AUM Growth
+$771M
(-6%)
Cap. Flow
-$419M
Cap. Flow
% of AUM
-54.35%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
–
Reduced
3
Closed
1
Top Buys
| 1 |
UBX
Unity Biotechnology
UBX
|
$3.97M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$360M |
| 2 |
Denali Therapeutics
DNLI
|
$46M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$17.2M |
| 4 |
ZY
Zymergen Inc. Common Stock
ZY
|
$147K |
Sector Composition
| 1 | Healthcare | 98.27% |
| 2 | Financials | 1.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $295M | 38.28% | 1,312,872 -1,600,000 | -55% | -$360M |
|
|
EQRX
2
DELISTED
EQRx, Inc. Common Stock
EQRX
| $180M | 23.32% | 36,335,375 | – | – |
|
|
3
Denali Therapeutics
DNLI
$2.23B
| $113M | 14.6% | 3,668,749 -1,500,000 | -29% | -$46M |
|
4
Erasca
ERAS
$445M
| $86.2M | 11.18% | 11,055,554 | – | – |
|
|
VERV
5
DELISTED
Verve Therapeutics
VERV
| $69M | 8.95% | 2,008,809 -500,000 | -20% | -$17.2M |
|
|
REVH
6
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
| $13.3M | 1.73% | 1,357,237 | – | – |
|
|
OMIC
7
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $9.5M | 1.23% | 3,798,926 | – | – |
|
|
UBX
8
DELISTED
Unity Biotechnology
UBX
| $3.97M | 0.51% | +10,048,181 | New | +$3.97M |
|
|
MTCR
9
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $1.43M | 0.18% | 2,940,503 | – | – |
|
|
RUBY
10
DELISTED
Rubius Therapeutics, Inc
RUBY
| $152K | 0.02% | 349,908 | – | – |
|
|
ZY
11
DELISTED
Zymergen Inc. Common Stock
ZY
| – | – | -119,205 | Closed | -$147K |
|